

# Mary Eapen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/571168/publications.pdf>

Version: 2024-02-01

147  
papers

7,907  
citations

81839

39  
h-index

53190

85  
g-index

148  
all docs

148  
docs citations

148  
times ranked

5985  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1097-1104.e2.	1.5	16
2	Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 109.e1-109.e8.	0.6	12
3	Long-term Survival after Hematopoietic Cell Transplant for Sickle Cell Disease Compared to the United States Population. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 325.e1-325.e7.	0.6	7
4	Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 406.e1-406.e6.	0.6	4
5	Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 409.e1-409.e10.	0.6	26
6	Cost effectiveness of reduced intensity conditioning and transplantation of unrelated umbilical cord blood versus HLA haploidentical related bone marrow for adults with hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6591-6591.	0.8	0
7	Comparison of total body irradiation &lt;i>versus</i> non-total body irradiation containing regimens for de novo acute myeloid leukemia in children. <i>Haematologica</i> , 2021, 106, 1839-1845.	1.7	13
8	Hematopoietic Stem Cell Transplantation Positively Affects the Natural History of Cancer in Nijmegen Breakage Syndrome. <i>Clinical Cancer Research</i> , 2021, 27, 575-584.	3.2	13
9	A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2021, 137, 983-993.	0.6	20
10	Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. <i>Blood</i> , 2021, 137, 420-428.	0.6	119
11	Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. <i>Blood Advances</i> , 2021, 5, 975-983.	2.5	27
12	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. <i>Leukemia</i> , 2021, 35, 2076-2085.	3.3	28
13	HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis. <i>Blood</i> , 2021, 138, 273-282.	0.6	88
14	Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning. <i>Blood Advances</i> , 2021, 5, 4064-4072.	2.5	17
15	Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 993.e1-993.e8.	0.6	4
16	Engraftment of Double Cord Blood Transplantation after Nonmyeloablative Conditioning with Escalated Total Body Irradiation Dosing to Facilitate Engraftment in Immunocompetent Patients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 879.e1-879.e3.	0.6	0
17	Since everyone has a donor, why are some eligible patients still not transplanted?. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101321.	0.7	1
18	Outcomes in Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia. <i>Transplantation and Cellular Therapy</i> , 2021, 28, 101.e1-101.e1.	0.6	7

#	ARTICLE	IF	CITATIONS
19	Long-Term Survival and Late Death after Hematopoietic Cell Transplant for Patients with Sickle Cell Disease Surviving for at Least Two-Years after Transplantation. <i>Blood</i> , 2021, 138, 410-410.	0.6	0
20	Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101. <i>Blood</i> , 2021, 138, 3956-3956.	0.6	0
21	Alternative donor transplantation for acute myeloid leukemia in patients aged $\leq 50$ years: young HLA-matched unrelated or haploidentical donor?. <i>Haematologica</i> , 2020, 105, 407-413.	1.7	23
22	A resurgence of cord blood transplantation?. <i>Lancet Haematology</i> , 2020, 7, e89-e90.	2.2	2
23	Hematopoietic Stem Cell Transplantation for Shwachman-Diamond Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1446-1451.	2.0	24
24	Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1930-1936.	2.0	10
25	The Effect of Granulocyte Colony-Stimulating Factor Use on Hospital Length of Stay after Allogeneic Hematopoietic Cell Transplantation: A Retrospective Multicenter Cohort Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2359-2364.	2.0	3
26	Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e161-e166.	2.0	38
27	Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease. <i>Blood</i> , 2020, 136, 623-626.	0.6	26
28	Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. <i>Journal of Clinical Oncology</i> , 2020, 38, 1518-1526.	0.8	34
29	Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e177-e182.	2.0	378
30	Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens. <i>Blood</i> , 2020, 136, 21-22.	0.6	0
31	Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplant for Hyperinflammatory Inborn Errors of Immunity. <i>Blood</i> , 2020, 136, 36-37.	0.6	0
32	Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. <i>Blood</i> , 2019, 134, 924-934.	0.6	199
33	In-vivo T-cell depletion: burden of morbidity versus survival. <i>Lancet Haematology</i> , 2019, 6, e63-e64.	2.2	0
34	Myeloablative vs reduced intensity T-cell replete haploidentical transplantation for hematologic malignancy. <i>Blood Advances</i> , 2019, 3, 2836-2844.	2.5	38
35	PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. <i>Blood Advances</i> , 2019, 3, 360-369.	2.5	92
36	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. <i>Blood Advances</i> , 2019, 3, 3123-3131.	2.5	37

#	ARTICLE	IF	CITATIONS
37	Related and unrelated donor transplantation for $\beta^2$ -thalassemia major: results of an international survey. <i>Blood Advances</i> , 2019, 3, 2562-2570.	2.5	48
38	Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. <i>Lancet Haematology</i> , 2019, 6, e585-e596.	2.2	128
39	Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50 Years or Older with Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 488-495.	2.0	21
40	Functional and Radiologic Assessment of the Brain after Reduced-Intensity Unrelated Donor Transplantation for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network Study 0601. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e174-e178.	2.0	21
41	Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 301-306.	2.0	27
42	Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor. <i>Blood</i> , 2019, 134, 3323-3323.	0.6	2
43	A Phase II Trial to Compare Allogeneic Transplant Vs. Standard of Care for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 1503. <i>Blood</i> , 2019, 134, 4592-4592.	0.6	0
44	Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. <i>Haematologica</i> , 2018, 103, 717-727.	1.7	38
45	Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1463-1470.	2.0	31
46	Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 322-328.e10.	1.5	79
47	Practice pattern changes and improvements in hematopoietic cell transplantation for primary immunodeficiencies. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 2004-2007.	1.5	14
48	Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity. <i>Blood Advances</i> , 2018, 2, 2095-2103.	2.5	66
49	Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. <i>Blood Advances</i> , 2018, 2, 299-307.	2.5	69
50	Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?. <i>Blood Advances</i> , 2018, 2, 1180-1186.	2.5	35
51	Is a matched sibling the ideal donor for hematopoietic cell transplant?. <i>Haematologica</i> , 2018, 103, 1251-1252.	1.7	0
52	Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. <i>Blood</i> , 2018, 132, 1438-1451.	0.6	78
53	Bone Marrow versus Peripheral Blood from Unrelated Donors for Children and Adolescents with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2487-2492.	2.0	19
54	Surviving childhood cancer: a sobering story. <i>Blood</i> , 2018, 131, 2603-2604.	0.6	1

#	ARTICLE	IF	CITATIONS
55	T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes. <i>Blood</i> , 2018, 132, 1015-1015.	0.6	2
56	Related and Unrelated Donor Transplantation for $\beta^2$ Thalassemia Major: Results of an International Survey. <i>Blood</i> , 2018, 132, 308-308.	0.6	1
57	Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. <i>Cancer</i> , 2017, 123, 2025-2034.	2.0	48
58	The effect of inter-unit HLA matching in double umbilical cord blood transplantation for acute leukemia. <i>Haematologica</i> , 2017, 102, 941-947.	1.7	15
59	Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1523-1530.	2.0	13
60	Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. <i>Haematologica</i> , 2017, 102, 1291-1298.	1.7	38
61	Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. <i>Blood</i> , 2017, 129, 1548-1556.	0.6	340
62	Relapsed acute lymphoblastic leukemia: Is it crucial to achieve molecular remission prior to transplant?. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 317-319.	0.7	3
63	Relationship between Mixed Donor Recipient Chimerism and Disease Recurrence after Hematopoietic Cell Transplantation for Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2178-2183.	2.0	74
64	Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1714-1721.	2.0	24
65	HCT for SCID: one size does not fit all. <i>Blood</i> , 2017, 129, 2826-2827.	0.6	0
66	Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis. <i>Lancet Haematology</i> , 2017, 4, e325-e333.	2.2	72
67	Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Children and Adolescents with Fanconi Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 310-317.	2.0	50
68	Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2017, 35, 3002-3009.	0.8	255
69	Selecting between HLA-Matched Siblings and HLA- Haploidentical Related Donors for Acute Leukemia in the Era of Post-Transplant Cyclophosphamide: The Center for International Blood and Marrow Transplant Registry and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplant. <i>Blood</i> , 2017, 130, 851-851.	0.6	1
70	Donor and recipient sex in allogeneic stem cell transplantation: what really matters. <i>Haematologica</i> , 2016, 101, 1260-1266.	1.7	54
71	Long-term Survival, Organ Function, and Malignancy after Hematopoietic Stem Cell Transplantation for Fanconi Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1257-1263.	2.0	56
72	Changing Trends of Unrelated Umbilical Cord Blood Transplantation for Hematologic Diseases in Patients Older than Fifty Years: A Eurocord-Center for International Blood and Marrow Transplant Research Survey. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1717-1720.	2.0	9

#	ARTICLE	IF	CITATIONS
73	Killer Cell Immunoglobulin-Like Receptorâ€“Ligand Matching and Outcomes after Unrelated Cord Blood Transplantation in Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1284-1289.	2.0	28
74	The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. <i>Blood</i> , 2016, 127, 260-267.	0.6	245
75	A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. <i>Blood</i> , 2016, 128, 2561-2567.	0.6	174
76	Umbilical Cord Blood (UCB) Transplantation in Children with Acute Leukemia: Impact of Conditioning Regimen on Transplant Outcomes. <i>Blood</i> , 2016, 128, 1231-1231.	0.6	1
77	Comparison of Peripheral Blood Stem Cells (PBSC) to Bone Marrow (BM) for T-Replete HLA-Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. <i>Blood</i> , 2016, 128, 683-683.	0.6	3
78	InÂVivo T Cell Depletion with Myeloablative Regimens on Outcomes after Cord Blood Transplantation for Acute Lymphoblastic Leukemia in Children. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2173-2179.	2.0	21
79	Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. <i>Blood</i> , 2015, 126, 1033-1040.	0.6	565
80	Hematopoietic cell transplantation for acute leukemia: selecting donors. <i>Haematologica</i> , 2015, 100, 414-415.	1.7	1
81	Effect of Cord Blood Processing on Transplantation Outcomes after Single Myeloablative Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 688-695.	2.0	16
82	Bone Marrow or Peripheral Blood for Reduced-Intensity Conditioning Unrelated Donor Transplantation. <i>Journal of Clinical Oncology</i> , 2015, 33, 364-369.	0.8	51
83	Hematopoietic stem cell transplantation for infantile osteopetrosis. <i>Blood</i> , 2015, 126, 270-276.	0.6	89
84	Transplantation Outcomes for Children with Hypodiploid Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1273-1277.	2.0	24
85	Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning. <i>British Journal of Haematology</i> , 2015, 169, 711-718.	1.2	56
86	Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1790-1795.	2.0	9
87	Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1â€“2 dose de-escalation study. <i>Lancet Haematology</i> , the, 2015, 2, e367-e375.	2.2	64
88	Long-Term Survival after Transplantation of Unrelated Donor Peripheral Blood or Bone Marrow Hematopoietic Cells for Hematologic Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 55-59.	2.0	34
89	Hematopoietic Stem Cell Transplantation from HLA Identical Sibling For Sickle Cell Disease an International Survey on Behalf of Eurocord-Monacord, EBMT Paediatric Disease Working Party and CIBMTR. <i>Blood</i> , 2015, 126, 541-541.	0.6	4
90	A Multicenter Phase II Trial of Unrelated Donor Reduced Intensity Bone Marrow Transplantation for Children with Severe Sickle Cell Disease (SCURT): Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0601) Study. <i>Blood</i> , 2015, 126, 619-619.	0.6	5

#	ARTICLE	IF	CITATIONS
91	Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014, 99, 1868-1875.	1.7	19
92	Unrelated donor transplantation: Peripheral blood or bone marrow – Does it matter?. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 278-282.	0.7	6
93	Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimen. <i>Haematologica</i> , 2014, 99, 1509-1515.	1.7	48
94	Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 662-667.	2.0	25
95	Outcomes after Hematopoietic Stem Cell Transplantation for Children with I-Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1847-1851.	2.0	150
96	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 202-208.	2.0	33
97	Alternative Donor Transplantation for Older Patients with Acute Myeloid Leukemia in First Complete Remission: A Center for International Blood and Marrow Transplant Research-Eurocord Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 816-822.	2.0	80
98	Low CD34 Dose Is Associated with Poor Survival after Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1418-1425.	2.0	40
99	Mismatched Related and Unrelated Donors for Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1485-1492.	2.0	43
100	Superiority of Pediatric Chemotherapy over Allogeneic Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult ALL in First Complete Remission: A Combined Analysis of Dana-Farber ALL Consortium and CIBMTR Cohorts. <i>Blood</i> , 2014, 124, 319-319.	0.6	6
101	Survival after T-Cell Replete Haplo-Identical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor Transplant for Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 679-679.	0.6	8
102	Comparable 3-Year Disease-Free Survival Regardless of Anti-Thymocyte Globulin Inclusion in Pediatric Myeloablative Cord Blood Transplantation for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 1259-1259.	0.6	0
103	Is There Any Effect of Killer Cell Immunoglobulin-like Receptor (KIR) on Outcomes after Single Unrelated Cord Blood Transplantation?. <i>Blood</i> , 2014, 124, 48-48.	0.6	1
104	Alternative Donor Hematopoietic Transplantation For Patients Older Than 50 Years With AML In First Complete Remission: Unrelated Donor and Umbilical Cord Blood Transplantation Outcomes. <i>Blood</i> , 2013, 122, 302-302.	0.6	0
105	Allogeneic transplantation for aplastic anemia. <i>Hematology</i> , 2012, 17, s15-s17.	0.7	5
106	Long-Term Survival and Late Deaths after Hematopoietic Cell Transplantation for Primary Immunodeficiency Diseases and Inborn Errors of Metabolism. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1438-1445.	2.0	37
107	No Survival Advantage After Double Umbilical Cord Blood (UCB) Compared to Single UCB Transplant in Children with Hematological Malignancy: Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0501) Randomized Trial. <i>Blood</i> , 2012, 120, 359-359.	0.6	11
108	Outcome of Transplantation for Acute Leukemia in Down Syndrome. <i>Blood</i> , 2012, 120, 1991-1991.	0.6	0

#	ARTICLE	IF	CITATIONS
109	The Effect of Transplant Center Characteristics On Survival After Pediatric Hematopoietic Cell Transplantation. <i>Blood</i> , 2012, 120, 762-762.	0.6	1
110	Hematopoietic Cell Transplant Versus Chemotherapy As Consolidation Treatment for Pediatric AML with Poor-Risk Cytogenetics. <i>Blood</i> , 2012, 120, 127-127.	0.6	0
111	Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. <i>Lancet Oncology</i> , The, 2011, 12, 1214-1221.	5.1	192
112	Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. <i>Blood</i> , 2011, 118, 282-288.	0.6	549
113	Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. <i>Blood</i> , 2011, 118, 2618-2621.	0.6	131
114	Graft-Versus-Host Disease (GVHD) Induced Graft-Versus-Leukemia (GVL) Effect: More Impact on Later Relapse and Disease-Free Survival Following Reduced Intensity Conditioning. <i>Blood</i> , 2011, 118, 1014-1014.	0.6	1
115	Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia (SAA): Serious and Unexpected Adverse Events in Pre-Defined Cyclophosphamide (CY) Dose Levels. <i>Blood</i> , 2011, 118, 3009-3009.	0.6	0
116	Effect of Race on Outcomes After Allogeneic Hematopoietic Cell Transplantation for Severe Aplastic Anemia. <i>Blood</i> , 2011, 118, 1020-1020.	0.6	6
117	Alternative Donor Transplantation for Aplastic Anemia. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 43-46.	0.9	19
118	Bone Marrow or Peripheral Blood. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 868-869.	2.0	1
119	Transplant Outcomes in Acute Leukemia (I). <i>Seminars in Hematology</i> , 2010, 47, 46-50.	1.8	13
120	Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. <i>Lancet Oncology</i> , The, 2010, 11, 653-660.	5.1	532
121	Impact of In Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies. <i>Blood</i> , 2010, 116, 2305-2305.	0.6	1
122	Transplant Conditioning Regimens and Outcomes After Allogeneic Hematopoietic Cell Transplantation (HCT) In Children and Adolescents with Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2010, 116, 3506-3506.	0.6	1
123	Reduced Intensity Conditioning (RIC) Transplantation In Acute Leukemia: The Effect of Source of Unrelated Donor Stem Cells on Outcomes. <i>Blood</i> , 2010, 116, 908-908.	0.6	1
124	Chronic Graft-Versus-Host Disease and Its Association with Treatment-Related Mortality, Relapse, Leukemia-Free and Overall Survival After Umbilical Cord Blood Transplantation (UCBT) In Children and Adolescents with Acute Leukemia. <i>Blood</i> , 2010, 116, 213-213.	0.6	0
125	Effect of Stem Cell Source From Unrelated Donors on Transplant Outcomes In Severe Aplastic Anemia (SAA): a Comparison of Unrelated Bone Marrow (BM) and Peripheral Blood Progenitor Cells (PBPC). <i>Blood</i> , 2010, 116, 531-531.	0.6	0
126	Analysis of Risk Factors Influencing Outcomes After Unrelated Cord Blood Transplantation In Children with Juvenile Myelomonocytic Leukemia. <i>An Eurocord, EBMT, EWOG-MDS, CIBMTR Study</i> . <i>Blood</i> , 2010, 116, 533-533.	0.6	2



#	ARTICLE	IF	CITATIONS
127	The Presence of HLA DR15 Antigen in Patients with Severe Aplastic Anemia Does Not Impact Engraftment and Survival After HLA-Identical Sibling Transplantation.. Blood, 2009, 114, 2280-2280.	0.6	1
128	Principles and analysis of hematopoietic stem cell transplantation outcomes: the physician's perspective. Lifetime Data Analysis, 2008, 14, 379-388.	0.4	11
129	HLA-Matched Sibling Hematopoietic Stem Cell Transplantation for Fanconi Anemia: Comparison of Irradiation and Nonirradiation Containing Conditioning Regimens. Biology of Blood and Marrow Transplantation, 2008, 14, 1141-1147.	2.0	69
130	Effect of Stem Cell Source on Transplant Outcomes in Adults with Acute Leukemia: A Comparison of Unrelated Bone Marrow (BM), Peripheral Blood (PB) and Cord Blood (CB). Blood, 2008, 112, 151-151.	0.6	4
131	Donor-Recipient Matching at the HLA-C Locus and Early Outcomes after Unrelated Umbilical Cord Blood Transplant (UCBT). Blood, 2008, 112, 153-153.	0.6	2
132	Hematopoietic Recovery and Overall Survival after HLA-Matched Sibling Transplants for Older Patients with Severe Aplastic Anemia (SAA).. Blood, 2008, 112, 2169-2169.	0.6	1
133	Risks and Benefits of Unrelated Donor Peripheral Blood Progenitor Cells (PBPC) in Children and Adolescents with Acute Leukemia.. Blood, 2008, 112, 977-977.	0.6	0
134	Encouraging Results after Alternative Donor Transplantation for Myelodysplastic Syndrome.. Blood, 2008, 112, 1964-1964.	0.6	0
135	Donor Characteristics Affecting Graft Failure and Survival after Unrelated Donor Transplantation with Reduced Intensity Conditioning Regimens (RIC) for Hematologic Malignancies.. Blood, 2008, 112, 1968-1968.	0.6	0
136	Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival. Biology of Blood and Marrow Transplantation, 2007, 13, 1461-1468.	2.0	174
137	Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet, The, 2007, 369, 1947-1954.	6.3	751
138	Risk Factors and Outcome after Second HLA-Matched Sibling Donor Transplantation for Graft Failure after a First HLA-Matched Sibling Transplant in Severe Aplastic Anemia.. Blood, 2007, 110, 1110-1110.	0.6	0
139	Risk Factors for Graft Failure and Mortality after HLA-Matched Sibling Donor Transplant for Severe Aplastic Anemia in Brazil.. Blood, 2007, 110, 622-622.	0.6	1
140	Rapid Transport and Infusion of Hematopoietic Stem Cells Can Improve Outcome after Unrelated Donor Transplant.. Blood, 2007, 110, 3063-3063.	0.6	1
141	Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood, 2006, 107, 4961-4967.	0.6	154
142	Comparable Long-Term Survival After Unrelated and HLA-Matched Sibling Donor Hematopoietic Stem Cell Transplantations for Acute Leukemia in Children Younger Than 18 Months. Journal of Clinical Oncology, 2006, 24, 145-151.	0.8	93
143	Use of Peripheral Blood Grafts Is Associated with Increased Acute and Chronic Graft-Versus-Host Disease without Improved Survival after Unrelated Donor Transplantation.. Blood, 2005, 106, 443-443.	0.6	4
144	Outcomes after HLA-Matched Sibling Transplants or Chemotherapy in Children with Acute Lymphoblastic Leukemia in Second Remission: A Collaborative Study of the Children's Oncology Group (COG) and the Center for International Blood and Marrow Transplant Research (CIBMTR).. Blood, 2005, 106, 174-174.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Higher Mortality After Allogeneic Peripheral-Blood Transplantation Compared With Bone Marrow in Children and Adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. <i>Journal of Clinical Oncology</i> , 2004, 22, 4872-4880.	0.8	246
146	Unrelated Donor Transplantation for Fanconi Anemia: Analysis of Prognostic Factors Impacting Engraftment and Survival.. <i>Blood</i> , 2004, 104, 824-824.	0.6	2
147	Family Cord Blood Banking: Experience and Views of Pediatric Hematopoietic Stem Cell Transplant Physicians.. <i>Blood</i> , 2004, 104, 3323-3323.	0.6	0